HB 1162 - AS INTRODUCED
2022 SESSION
22-2363
11/10
HOUSE BILL 1162
SPONSORS: Rep. Gay, Rock. 8; Rep. Bernardy, Rock. 16; Rep. Greeson, Graf. 16; Rep. Woods, Merr. 23; Rep. Rung, Hills. 21; Rep. Stapleton, Sull. 5
COMMITTEE: Commerce and Consumer Affairs
-----------------------------------------------------------------
ANALYSIS
This bill prohibits insurers from excluding coverage for any vaccination, device, or medication that has been authorized for emergency use by the United States Food and Drug Administration.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Explanation: Matter added to current law appears in bold italics.
Matter removed from current law appears [in brackets and struckthrough.]
Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.
22-2363
11/10
STATE OF NEW HAMPSHIRE
In the Year of Our Lord Two Thousand Twenty Two
Be it Enacted by the Senate and House of Representatives in General Court convened:
1 Accident and Health Insurance; Off-label Prescription Drugs; Individual. Amend RSA 415:6-g, III(b) to read as follows:
(b) Coverage for experimental or investigational drugs, vaccinations, devices, or medications, or the reactions to them, not approved for any indication by the FDA, provided that reactions to any vaccination, device, or medication that has been authorized for emergency use by the FDA shall not be excluded; and
2 Accident and Health Insurance; Off-label Prescription Drugs; Group. Amend RSA 415:18-j, III(b) to read as follows:
(b) Coverage for experimental or investigational drugs, vaccinations, devices, or medications, or the reactions to them, not approved for any indication by the FDA, provided that reactions to any vaccination, device, or medication that has been authorized for emergency use by the FDA shall not be excluded; and
3 Effective Date. This act shall take effect 60 days after its passage.
| Date | Body | Type |
|---|---|---|
| Feb. 2, 2022 | House | Hearing |
| Feb. 2, 2022 | House | Hearing |
| March 3, 2022 | House | Exec Session |
| Oct. 26, 2022 | House | Exec Session |
| House | Floor Vote |
Oct. 27, 2022: Interim Study Report: Not Recommended for Future Legislation (Vote 17-0)
Oct. 10, 2022: Executive Session: 10/19/2022 10:00 am LOB 302-304
Sept. 28, 2022: Full Committee Work Session: 10/13/2022 01:45 pm LOB 302-304
March 15, 2022: Refer for Interim Study: MA VV 03/15/2022 HJ 6
March 9, 2022: Committee Report: Refer for Interim Study (Vote 17-1; CC)
Feb. 28, 2022: Subcommittee Work Session: 03/03/2022 10:00 am LOB 302-304
March 3, 2022: Executive Session: 03/03/2022 1:15 p.m. LOB302-304
Feb. 3, 2022: Subcommittee Work Session: 02/10/2022 01:15 pm LOB 302-304
Feb. 2, 2022: Public Hearing: 02/02/2022 10:45 a.m. LOB302-304
Feb. 2, 2022: Public Hearing: 02/02/2022 10:45 a.m. LOB302-304
Nov. 17, 2021: Introduced 01/05/2022 and referred to Commerce and Consumer Affairs
: To Be Introduced and referred to Commerce and Consumer Affairs